BioStock: BioInvent ready for combination studies with BT-001

BioInvent and its partner Transgene have reported positive results in the phase I/IIa study with the oncolytic virus BT-001. In 11 of the 18 included patients, the lesions were stabilised. In two patients, objective antitumour activity was also seen. This means that both partners can continue the evaluation as planned with the part of the study where BT-001 will be studied in combination with pembrolizumab.

Read the article about BioInvent at biostock.se:

https://www.biostock.se/en/2023/06/bioinvent-ready-for-combination-studies-with-bt-001/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/